Researchers have discovered that cystathionine reduces the development of toxin-induced liver and/or kidney disease and is also capable of blocking tunicamycin-mediated tissue injury and apoptosis. Findings suggest that cystathionine may be a new treatment option in many disease states where cell death is triggered by stress to the endoplasmic reticulum (ER), including several kidney and liver disease states as well as some kinds of cardiovascular disease. Neuroblastoma is also marked by massive accumulation of cystathionine. Researchers suggest that this accumulated cystathionine has the potential to allow the neuroblastoma cells to resist cytotoxic treatments such as chemotherapy and that the use of a cystathionine β-synthase (CBS)-inactivating drug could increase chemosensitization and improve clinical outcome in neuroblastoma patients.
Download Summary Document Here:
http://cuamc.technologypublisher.com/files/sites/cu2828h_ncs.pdf